

Announcement of Phase 1 study results of Imarikiren (SCO-272) at the 38<sup>th</sup> Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics

Sochia Pharma will present results from the Phase 1 clinical trial of Imarikiren (development code: SCO-272) at the 38<sup>th</sup> Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutic, held from December 7 to 9, 2017 at Pacifico Yokohama, Yokohama.

Session	Date, time and location	Title
Free Paper: Oral 03 Clinical studies/clinical trials (1)	Thursday, December 7, 2017 15:30-16:30  Room 6 (#413, Pacifico Yokohama 4F)	A Randomized, Single-center, Open-label, Single-dose Phase 1 Study to Evaluate the Effect of Difference in Ethnicity on the Pharmacokinetics of Imarikiren in the Healthy Adult Male Subjects

Contact for inquiries: [info@scohia.com](mailto:info@scohia.com)